For patients with HFrEF recovering from sepsis, how are you determining the timing of re-initiation of ARNI, SGLT2 inhibitors, and MRAs following transient hypotension or acute kidney injury?

A 2025 study of post-HF hospitalization practice patterns found substantial variability in GDMT initiation, discontinuation, and timing of re-initiation, highlighting that clinicians are still approaching this differently.